ReNeuron Group plc
("ReNeuron" or the "Company")
Directorate Changes
ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that Dr Tim Corn and Mark Evans have resigned as Non-Executive Directors of the Company and that Martin Walton has been appointed as a Non-Executive Director, all with immediate effect.
Following these changes, the ReNeuron Board now comprises of five directors as follows: Iain Ross (Executive Chairman); Catherine Isted (CFO and Executive Director) and three independent Non-Executive Directors - Dr Michael Owen, Barbara Staehelin and Martin Walton.
Iain Ross, Chairman of ReNeuron, commented: "On behalf of the Board and Management I would like to thank Tim Corn for his service to the Company over the last nine years and to recognise his contribution as a director and former Chairman of ReNeuron. Also, I want to thank Mark Evans for the invaluable support he has provided over the last two years as a director and representative of Obotritia, a significant shareholder in ReNeuron.
"I would like to welcome Martin Walton to the ReNeuron Board as we look to re-focus the business. Martin, a former investment banker, has completed more than 25 transactions in the last 12 years as a principal or advisor which has included start-up and spin-out investments, pre-IPO and IPO funding; M&A and over $1bn in investment and co-investment capital. He is the co-founder of LSE-listed Arix Bioscience plc (LSE: ARIX) and his current roles include serving as CEO of Excalibur Medicines Ltd and a Board Member of the Liverpool Life Sciences Accelerator Partnership. He brings a wealth of relevant experience in the life sciences sector."
As required under Schedule Two, paragraph (g) of the AIM Rules for Companies, further disclosures on Mr Walton are as follows:
Martin Charles Walton, aged 58, has held the following directorships and/or partnerships in the past five years:
|
Current directorships and/or partnerships: |
Past directorships and/or partnerships: |
|
Excalibur Medicines Ltd Bradshaw Consulting Ltd Interrad Medical Inc
|
Igraine plc Iatros Capital Limited Iota Sciences Limited Simbec-Orion Group Limited PZT Limited Anontec Limited Arix Capital Management Limited Arthurian Life Sciences Gp Limited Arthurian Life Sciences Spv Gp Limited Excalibur Fund Managers Limited |
There is no further information in respect of Mr Walton that is required to be disclosed under AIM Rule 17 or Schedule Two, paragraph (g) of the AIM Rules for Companies.
ENDS
Contacts:
|
ReNeuron |
|
|
Iain Ross, Chairman |
Via Walbrook PR |
|
Catherine Isted, Chief Financial Officer |
|
|
|
|
|
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking) |
+44 (0)20 3100 2000
|
|
|
|
|
Allenby Capital Limited (Joint Broker) |
+44 (0)20 3328 5656 |
|
James Reeve/George Payne (Corporate Finance) |
|
|
Stefano Aquilino (Sales & Corporate Broking) |
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
+44 (0)20 7933 8780 or reneuron@walbrookpr.com |
|
Paul McManus |
+44 (0)7980 541 893 |
About ReNeuron
ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.
ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
The Company has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-licence both these programmes in other territories.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
